search
Back to results

Celiac Disease in Childhood-Adulthood Transition (CeliCAT)

Primary Purpose

Celiac Disease, Celiac Disease in Children, Transition of Care

Status
Enrolling by invitation
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
CeliCAT form
Sponsored by
Tampere University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Celiac Disease focused on measuring celiac disease, adolescents, transition, follow-up, gluten-free diet, quality of life, health, symptoms

Eligibility Criteria

13 Years - 19 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • verified celiac disease diagnosis in childhood (<16 years of age)
  • age 13-19 years at recruitment
  • Finnish-speaking

Exclusion Criteria:

  • disease or condition preventing the completing of the study questionnaire

Inclusion criteria for controls

  • no celiac disease diagnosis
  • age 13-19 years at recruitment
  • Finnish-speaking

Sites / Locations

  • Kuopio University Hospital
  • South Karelia Central Hospital
  • Seinäjoki Central Hospital
  • Tampere Celiac Disease Research Center, Tampere University
  • Turku University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Structured transition

Routine practices

Arm Description

With the help of CeliCAT form

Outcomes

Primary Outcome Measures

Adherence to a gluten-free diet
Assessed with questionnaire, celiac autoantibodies and urine GIP
Change in adherence to a gluten-free diet
Assessed with questionnaire, celiac autoantibodies and urine GIP
Transition readiness
Assessed with questionnaire
Change in transition readiness
Assessed with questionnaire

Secondary Outcome Measures

General health and health concerns
Assessed with questionnaire
Change in general health and health concerns
Assessed with questionnaire
Symptoms
Assessed with questionnaire
Change in symptoms
Assessed with questionnaire
Quality of life
Assessed with questionnaire
Change in quality of life
Assessed with questionnaire
Costs
Assessed with questionnaire
Abnormalities in follow-up laboratory evaluations
Assessed with blood sample
Abnormalities in physical examination
Assessed with medical examination

Full Information

First Posted
September 27, 2021
Last Updated
August 11, 2023
Sponsor
Tampere University Hospital
Collaborators
Tampere University, Kuopio University Hospital, Turku University Hospital, Seinajoki Central Hospital, South Carelia Central Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05084937
Brief Title
Celiac Disease in Childhood-Adulthood Transition
Acronym
CeliCAT
Official Title
Celiac Disease in Childhood-Adulthood Transition (CeliCAT)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
December 2026 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tampere University Hospital
Collaborators
Tampere University, Kuopio University Hospital, Turku University Hospital, Seinajoki Central Hospital, South Carelia Central Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Aims of this study are to evaluate adolescents with celiac disease during their transition from pediatrics to adult care, and to develop better healthcare follow-up practices.
Detailed Description
Celiac disease is one of the most common chronic gastrointestinal diseases affecting 1-3% of population worldwide. It is treated with life-long and strict gluten-free diet. When dietary treatment is successful, prognosis of pediatric patients seems to be excellent whereas ongoing predisposition to gluten may increase the risk even to permanent complications. However, gluten-free diet may cause burden and restrictions in everyday life impairing quality of life. Regular follow-up is recommended to support the treatment and to detect early possible comorbidities and complications, but, in practice, patients are often lost to follow-up. Studies about the significance of follow-up and its optimal implementation are scarce. Pediatric patients form a special group here as they may not even remember the reason for the diagnosis if it was set in early childhood, and the education about the disease and its treatment are often given primarily to the caregivers. Responsibility of the treatment shifts to patients themselves in adolescence at the same time with other significant changes in life and they have more often challenges with gluten-free diet than other patients. Despite this, studies about the transition from pediatrics to adult-care are very few. This study evaluates 13-19 years old patients diagnosed with celiac disease in childhood (<16 years of age) and compares them to adolescents without celiac disease in selected variables. Study focuses on healthcare follow-up practices and pilot a CeliCAT transition form in a randomized, controlled study design. The main hypothesis is that structured follow-up and transition of pediatric patients to adult care predicts better health, quality of life and adherence to the dietary treatment later in life. Data is collected with physical examination, questionnaires and with blood and urine samples. Follow-up is arranged at one and three years from the first visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Celiac Disease, Celiac Disease in Children, Transition of Care, Follow-up, Diet, Gluten-Free
Keywords
celiac disease, adolescents, transition, follow-up, gluten-free diet, quality of life, health, symptoms

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Structured transition form is used with 50% of the study patients
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Structured transition
Arm Type
Active Comparator
Arm Description
With the help of CeliCAT form
Arm Title
Routine practices
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
CeliCAT form
Intervention Description
Systematic summary to support transition
Primary Outcome Measure Information:
Title
Adherence to a gluten-free diet
Description
Assessed with questionnaire, celiac autoantibodies and urine GIP
Time Frame
At the onset of the study
Title
Change in adherence to a gluten-free diet
Description
Assessed with questionnaire, celiac autoantibodies and urine GIP
Time Frame
After 1 and 3 years
Title
Transition readiness
Description
Assessed with questionnaire
Time Frame
At the onset of the study
Title
Change in transition readiness
Description
Assessed with questionnaire
Time Frame
After 1 and 3 years
Secondary Outcome Measure Information:
Title
General health and health concerns
Description
Assessed with questionnaire
Time Frame
At the onset of the study
Title
Change in general health and health concerns
Description
Assessed with questionnaire
Time Frame
After 1 and 3 years
Title
Symptoms
Description
Assessed with questionnaire
Time Frame
At the onset of the study
Title
Change in symptoms
Description
Assessed with questionnaire
Time Frame
After 1 and 3 years
Title
Quality of life
Description
Assessed with questionnaire
Time Frame
At the onset of the study
Title
Change in quality of life
Description
Assessed with questionnaire
Time Frame
After 1 and 3 years
Title
Costs
Description
Assessed with questionnaire
Time Frame
At the onset of the study
Title
Abnormalities in follow-up laboratory evaluations
Description
Assessed with blood sample
Time Frame
At the onset of the study
Title
Abnormalities in physical examination
Description
Assessed with medical examination
Time Frame
At the onset of the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: verified celiac disease diagnosis in childhood (<16 years of age) age 13-19 years at recruitment Finnish-speaking Exclusion Criteria: disease or condition preventing the completing of the study questionnaire Inclusion criteria for controls no celiac disease diagnosis age 13-19 years at recruitment Finnish-speaking
Facility Information:
Facility Name
Kuopio University Hospital
City
Kuopio
Country
Finland
Facility Name
South Karelia Central Hospital
City
Lappeenranta
Country
Finland
Facility Name
Seinäjoki Central Hospital
City
Seinäjoki
Country
Finland
Facility Name
Tampere Celiac Disease Research Center, Tampere University
City
Tampere
Country
Finland
Facility Name
Turku University Hospital
City
Turku
Country
Finland

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Celiac Disease in Childhood-Adulthood Transition

We'll reach out to this number within 24 hrs